I don’t think they are looking back with Herceptin - the drug has netted them billions of dollars since 2006 and they have others like it. If anything, biosimilars might be bad for HER-Vaxx, the whole point was that HER-Vaxx is a cheaper option to Herceptin, but with the introduction of biosimilars, Herceptin and drugs similar to it will also drop.
HER-Vaxx’s market will probably be for companies with existing immune checkpoint inhibitors targeting different bio markers that are looking to expand the indication and usability of their drug. This is where IMU seems to be trending towards.
Ann: Imugene HER-Vaxx Phase 2 PFS Data and Flags Three New Trials, page-122
-
- There are more pages in this discussion • 224 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.2¢ |
Change
-0.001(1.89%) |
Mkt cap ! $382.1M | |||
| Open | High | Low | Value | Volume |
| 5.3¢ | 5.4¢ | 5.2¢ | $216.1K | 4.106M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 31 | 1854997 | 5.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.3¢ | 382882 | 4 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| IMU (ASX) Chart |